We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Even after the Group of Eight (G8) nation's meeting on global health, one issue has not been settled: finance mechanisms to pay for vaccines and medicines needed by developing countries in Africa and elsewhere.
Outside experts who advise the government on drugs and other regulated products often have financial ties to industry, creating the potential for conflicts of interest.
The European Commission has granted marketing authorization to Bayer and Onyx Pharmaceuticals for Nexavar (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer, who have failed prior interferon-alpha or interleukin-2 based therapy, or when the patients are considered unsuitable for such therapy.
South Centre, an intergovernmental organization of developing countries in Asia, Africa and Latin America, has stated that developing countries should allow regulatory authorities to approve generic drugs on the basis of the originator data from the time of its submission.
The Central Government initiative to amend the Schedule K of the Drugs and Cosmetics (D&C) Act and Rules and to allow sale of medicines categorized as household remedies in any shop across the country will have to face stiff opposition from the organized drug trade.
Australian pharmaceutical company Pharmaxis Ltd. has lodged the registration documents for marketing approval of its asthma management product, Aridol, with the Swiss regulatory agency for therapeutic products, Swissmedic.
Valera Pharmaceuticals, Inc. announced a partnership with Spepharm Holding B.V. for the exclusive marketing and distribution rights to VANTAS and SUPPRELIN-LA in the European Union, Switzerland and Norway.
Before the proposed visit of the prime minister of India, Dr Manmohan Singh, to Tanzania in September 2006, a high level delegation consisting of government officials and leading businessmen from Tanzania would be visiting India in the third week of August for interacting with Indian businessmen.
YM BioSciences Inc., a company engaged in the acquisition, development and commercialization of oncology and acute care products, has reported that India's Drug Controller General has granted marketing approval to nimotuzumab, an anti-EGFr monoclonal antibody, for the treatment of head & neck cancer.